Elvio Grazioso Russi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7792774/publications.pdf

Version: 2024-02-01

86 papers

2,395 citations

201674 27 h-index 223800 46 g-index

86 all docs

86 docs citations

86 times ranked 3883 citing authors

#	Article	IF	CITATIONS
1	Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Management and Research, 2017, Volume 9, 363-371.	1.9	150
2	Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. International Journal of Radiation Oncology Biology Physics, 2020, 107, 597-599.	0.8	127
3	Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience. Clinical and Experimental Otorhinolaryngology, 2016, 9, 287-297.	2.1	118
4	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	4.4	112
5	Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: Review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treatment Reviews, 2012, 38, 1033-1049.	7.7	106
6	Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations. Clinical and Experimental Otorhinolaryngology, 2013, 6, 117.	2.1	106
7	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 372-384.	4.4	95
8	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. Oncologist, 2011, 16, 228-238.	3.7	94
9	Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. Radiation Oncology, 2014, 9, 264.	2.7	84
10	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	4.4	82
11	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. Critical Reviews in Oncology/Hematology, 2016, 99, 100-106.	4.4	62
12	State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013. Oncology, 2014, 86, 212-229.	1.9	61
13	Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy. International Journal of Cardiology, 2018, 255, 175-183.	1.7	57
14	<i>Lactobacillus brevis</i> CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study. Anticancer Research, 2019, 39, 1935-1942.	1.1	55
15	Unusual relapse of hepatocellular carcinoma. Cancer, 1992, 70, 1483-1487.	4.1	51
16	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	4.4	51
17	Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. Mediators of Inflammation, 2014, 2014, 1-14.	3.0	48
18	A systematic review of current and emerging approaches in the field of larynx preservation. Radiotherapy and Oncology, 2014, 110, 16-24.	0.6	47

#	Article	IF	CITATIONS
19	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 167-182.	4.4	46
20	Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncology, 2012, 48, 1051-1057.	1.5	44
21	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	7.7	40
22	Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Investigational New Drugs, 2015, 33, 310-320.	2.6	34
23	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 95, 191-213.	4.4	33
24	Role of IL-8 induced angiogenesis in uveal melanoma. Investigational New Drugs, 2013, 31, 1107-1114.	2.6	32
25	AÂcomparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 877-889.	2.0	31
26	Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Lung Cancer, 2002, 37, 201-206.	2.0	30
27	A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. European Journal of Internal Medicine, 2018, 53, 73-78.	2.2	29
28	Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 407-415.	1.3	28
29	Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. Journal of Contemporary Brachytherapy, 2019, 11, 48-53.	0.9	26
30	Effect of Whole Brain Radiation on Local Cerebral Glucose Utilization in the Rat. Neurosurgery, 1991, 28, 491-495.	1.1	25
31	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive Care in Cancer, 2015, 23, 2231-2244.	2.2	25
32	Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. International Journal of Radiation Oncology Biology Physics, 2006, 65, 25-32.	0.8	24
33	Pros and Cons of the New Edition of TNM Classification of Head and Neck Squamous Cell Carcinoma. Oncology, 2018, 95, 202-210.	1.9	24
34	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health and Quality of Life Outcomes, 2018, 16, 122.	2.4	24
35	Postoperative Therapy in Head and Neck Cancer: State of the Art, Risk Subset, Prognosis and Unsolved Questions. Oncology, 2011, 81, 21-29.	1.9	23
36	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Supportive Care in Cancer, 2014, 22, 1889-96.	2.2	23

#	Article	IF	CITATIONS
37	Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Supportive Care in Cancer, 2011, 19, 1823-1830.	2.2	21
38	Contouring of the Pharyngeal Superior Constrictor Muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group. Radiotherapy and Oncology, 2014, 112, 337-342.	0.6	16
39	Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule. International Journal of Radiation Oncology Biology Physics, 2006, 66, 731-737.	0.8	15
40	Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Investigational New Drugs, 2013, 31, 59-65.	2.6	15
41	What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria. Critical Reviews in Oncology/Hematology, 2017, 111, 20-30.	4.4	15
42	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus, 2017, 3, 321-324.	3.1	15
43	Facial Basal Cell Carcinomas in Elderly Frail Patients Treated with Low Total-dose Radiotherapy. Anticancer Research, 2015, 35, 4949-53.	1.1	15
44	Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial. Radiotherapy and Oncology, 2005, 75, 193-196.	0.6	14
45	Ultrathin Hydrocolloid Dressing in Skin Damaged From Alternating Radiotherapy andÂChemotherapy Plus Cetuximab in Advanced Head and Neck Cancer (G.O.N.O. AlteRCC Italian Trial): In Regard to Macmillan etÂal. (IntÂJÂRadiat Oncol Biol Phys 2007;68:864–872). International Journal of Radiation Oncology Biology Physics, 2007, 69, 638-639.	0.8	12
46	Strategies for Non-Resectable Head and Neck Cancer. Current Treatment Options in Oncology, 2013, 14, 492-504.	3.0	12
47	Facial basal cell carcinomas treated with hypo-fractionated radiotherapy: A retrospective analysis in 117 elderly patients. Journal of the American Academy of Dermatology, 2015, 73, 166-168.	1.2	12
48	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT) Tj ETQe cyclophosphamide. Clinical and Translational Radiation Oncology, 2018, 12, 47-52.	0 0 0 rgB1 1.7	Overlock 1
49	Management of â€~In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy. Oncology, 2013, 85, 257-261.	1.9	11
50	Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Medical Oncology, 2020, 37, 85.	2.5	11
51	Palliative-radiotherapy in lumbosacral carcinomatous neuropathy. Radiotherapy and Oncology, 1993, 26, 172-173.	0.6	10
52	Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. Radiation Oncology, 2011, 6, 162.	2.7	10
53	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 1 Reviews in Oncology/Hematology, 2019, 134, 104-119.	0.784314 4.4	rgBT /Overlo
54	MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncology, 2012, 48, 602-607.	1.5	9

#	Article	IF	CITATIONS
55	A new approach for the pixel map sensitivity (PMS) evaluation of an electronic portal imaging device (EPID). Journal of Applied Clinical Medical Physics, 2013, 14, 234-250.	1.9	9
56	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. Dysphagia, 2019, 34, 52-62.	1.8	9
57	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.6	9
58	The cisplatin–irradiation combination suggests that apoptosis is not a major determinant of clonogenic death. Anti-Cancer Drugs, 2007, 18, 659-667.	1.4	8
59	Epidermal growth factor receptor-inhibitors and radiotherapy-induced cutaneous adverse effects: "Koebner-Phenomenon―or radio-dermatitis?. Radiotherapy and Oncology, 2009, 92, 142-143.	0.6	7
60	The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. Supportive Care in Cancer, 2012, 20, 2141-2147.	2.2	7
61	Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years' Follow-Up. International Journal of Biological Markers, 2016, 31, 183-192.	1.8	7
62	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq0 0 Reviews in Oncology/Hematology, 2019, 134, 87-103.	0 rgBT /O 4.4	verlock 10 Tf 7
63	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	1.6	6
64	External Beam Radiotherapy in Thyroid Carcinoma: Clinical Review and Recommendations of the AIRO "Radioterapia Metabolica―Group. Tumori, 2017, 103, 114-123.	1.1	5
65	Nonsurgical Conservative Approach for Laryngeal Cancer: What Information Should Patients Be Given?. Journal of Clinical Oncology, 2013, 31, 3168-3170.	1.6	4
66	Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey. Radiologia Medica, 2017, 122, 140-145.	7.7	4
67	How I treat squamous ENT cancer. ESMO Open, 2019, 4, e000542.	4.5	4
68	Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach. Cancer Reports, 2020, 3, e1285.	1.4	4
69	An Incidental Finding of Mucinous Colon Cancer by 18F-Choline PET/CT Determining a Change in Clinical Management of a Patient with Recurrent Prostate Adenocarcinoma. Case Reports in Oncological Medicine, 2014, 2014, 1-4.	0.3	3
70	Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC). Oral Oncology, 2020, 107, 104801.	1.5	3
71	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. Tumori, 2021, 107, 030089162092942.	1.1	3
72	External radiation therapy boost to the vaginal vault: feasibility of intracavitary dosimetry using a commercial diode system. International Journal of Radiation Oncology Biology Physics, 1999, 44, 221-226.	0.8	2

#	Article	IF	CITATIONS
73	Cetuximab-Related Radiation Dermatitis in Head-and-Neck Cancer Patients: In Regard to Studer etÂal. (Int) Tj ETQo 79, 1278.	q1 1 0.784 0.8	4314 rgBT / 2
74	Management of Oropharyngeal Mycosis in Head and Neck Cancer Occurring during (Chemo) Radiotherapy: An Italian Radio-Oncologist Survey. Tumori, 2015, 101, 312-317.	1.1	2
7 5	P16 Cutoff in Head and Neck Squamous Cell Carcinoma: Correlation between Tumor and Patient Characteristics and Outcome. International Journal of Biological Markers, 2016, 31, 44-52.	1.8	2
76	E1 Detection as Prognosticator in Human Papillomavirus-Positive Head and Neck Cancers. International Journal of Biological Markers, 2016, 31, 163-172.	1.8	2
77	Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. Tumori, 2019, 105, 161-167.	1.1	2
78	The value of prostate-specific antigen monitoring during salvage radiotherapy: a retrospective study and systematic review with meta-analysis. Journal of Radiation Oncology, 2019, 8, 413-423.	0.7	2
79	Consideration about axillary nodes and arm position. Radiotherapy and Oncology, 2006, 79, 352-353.	0.6	0
80	Adjuvant malignant mesothelioma radiotherapy: How many difficulties! In regard to: Allen et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma (Int J Radiat) Tj ETQq0 0 0 rg pleurectomy/decortication for malignant pleural mesothelioma (Int J Radiat Oncol Biol Phys) Tj ETQq0 0 0 rgBT /O	0.8	O
81	Radiotherapy in Pleural Malignant Mesothelioma: Why not! in Regard to Scorsetti et al. (Int J Radiat) Tj ETQq1 1 0. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279.		
82	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	2.4	0
83	A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy. Advances in Radiation Oncology, 2018, 3, 121-124.	1.2	О
84	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
85	Abstract 1876: Combination of PI3KCA targeting with irradiation: A preclinical study on head and neck cancer cell lines. , 2014, , .		O
86	Prognostic value of HPV detection with three primer sets in 255 Head-Neck cancers Journal of Clinical Oncology, 2015, 33, 6045-6045.	1.6	0